Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366

ASSEMBLY BIOSCIENCES, INC.

2025-Q3 EPS reported -$3.03 revenue$29,834,000

Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.
Cash, cash equivalents and marketable securities $232.6M as of Sep 30, 2025; projected to fund operations into late 2027.
Raised $175M gross proceeds from equity financing with institutional investors in August 2025.
Positive Phase 1b interim data for ABI-5366: significant reductions in HSV-2 shedding and genital lesion rates in recurrent genital herpes.
Phase 1a interim data for ABI-6250 supports progression to Phase 2; additional HSV data (ABI-5366, ABI-1179) expected by year-end.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.